Market Context
The broad-market trend is constructive, while the current market pulse is adverse and the market-risk posture is defensive. The current Healthcare sector pulse is mixed, while its short-term outlook is mixed, with no clear directional read. That current reading differs from the forward sector outlook. Broad-market measures include breadth of 24.14%, capitalization-weighted return of -1.04%, and equal-weight return of -1.79%. Healthcare measures include breadth of 34.02%, capitalization-weighted return of 1.78%, and equal-weight return of -1.26%.
PTGX — Protagonist Therapeutics Inc
WATCH LONG | October 14, 2026
Setup
PTGX remains a WATCH long setup, with the preferred entry zone anchored to established support.
Key Levels
- Reference Price (as of October 14, 2026): $136.16
- AIF Model Target: $154.52
- Reference upside: 13.48%
- Reference reward/risk: 3.00
- Preferred Entry Zone: $132.11–$136.70
- Entry Risk: 4.49% from entry
Why It Stands Out
Upward stock-level model direction across the immediate, near-term, medium-term, and longer-term horizons provides substantive support. Additional support comes from the fundamental profile and a defined reward/risk profile.
Risk & Timing
Sector conditions remain a material headwind.
Bottom Line
PTGX remains a WATCH long setup. The controlling evidence supports the WATCH classification.
Research Snapshot
Valuation & Fundamentals
Valuation measures include trailing P/E of 140.34x and forward P/E of 36.90x. Profitability measures include ROA of 4.55%, ROE of 11.00%, operating margin of 74.40% and net margin of 29.40%. Balance-sheet and volatility context includes total liabilities to equity of 0.09 and beta of 1.52. The Fundamental Sentiment Score is 0.42.
Technical Context
Historical ranges include 21-day range of $134.10–$152.19, 40-day range of $134.10–$152.19 and 52-week range of $73.08–$160.81.
Risks & Catalysts
Earnings are estimated for November 5, 2026 and remain an event risk.
